TOP TEN perturbations for 39968_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39968_at
Selected probe(set): 206480_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39968_at (206480_at) across 6674 perturbations tested by GENEVESTIGATOR:
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):2.4142275Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-2.1653023Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample
Relative Expression (log2-ratio):2.1392412Number of Samples:36 / 74
| Experimental | AML study 1 (t(15;17)(q22;q11-12)) |
| Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-1.959116Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-1.7845993Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)
Relative Expression (log2-ratio):1.7654476Number of Samples:8 / 8
| Experimental | endometriosis study 5 (endo. lesion; proliferative MCP) |
| Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle. | |
| Control | endometriosis study 5 (eutopic endometrium; proliferative MCP) |
| Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases. |
CML study 1 / normal bone marrow sample
Relative Expression (log2-ratio):1.5848475Number of Samples:75 / 74
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-1.4439182Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.4017725Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
lung squamous cell carcinoma study 1 / normal lung tissue
Relative Expression (log2-ratio):-1.2804146Number of Samples:31 / 44
| Experimental | lung squamous cell carcinoma study 1 |
| Primary lung squamous cell carcinoma samples of a patient with non-small cell lung cancer. | |
| Control | normal lung tissue |
| Histologically normal lung tissue. |